| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
07-18-2023, 02:44 PM
|
#1 | |||
|
||||
|
Legendary
|
JAMA. Published online July 17, 2023. doi:10.1001/jama.2023.13239
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial | Dementia and Cognitive Impairment | JAMA | JAMA Network Original Investigation July 17, 2023 Donanemab in Early Symptomatic Alzheimer Disease The TRAILBLAZER-ALZ 2 Randomized Clinical Trial ________________ Seems as if there's positive conclusions. Also noted the conflict in interest disclosures and funding and support. So far looks promising however. I hope so |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| We may be able to reverse signs of early Alzheimer’s disease | Parkinson's Disease | |||
| Early Alzheimer's Disease from head trauma | Alzheimer's Disease | |||
Donanemab in Early Symptomatic Alzheimer Disease
Linear Mode
